Evaluation of Immunogenicity, Safety and Reactogenicity of GSK Biologicals' dTpa Booster Vaccine (263855) (Boostrix) Administered as a Booster Dose in Healthy Russian Subjects
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 10 Aug 2018
At a glance
- Drugs DTaP vaccine (Primary)
- Indications Diphtheria; Pertussis; Tetanus
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 02 Aug 2018 Planned End Date changed from 4 Sep 2018 to 29 Aug 2018.
- 02 Aug 2018 Planned primary completion date changed from 4 Sep 2018 to 29 Aug 2018.
- 02 Aug 2018 Status changed from recruiting to active, no longer recruiting.